Cervical Health
All documents accessed through this site are for internal Hologic distribution only. If you would like to provide a copy of a document to a third party, please contact Adrian Vilalta for additional information
Peer-Reviewed Articles
Co-testing – Clinico and Economic Benefits Model
WHAT WAS EVALUATED
-
A health state transition (Markov) model with 1-year cycling was developed using epidemiologic, clinical, and economic data from healthcare databases and published literature.
-
A hypothetical cohort of one million women receiving triennial cervical cancer screening was simulated from ages 30 to 70 years.
-
Screening strategies compared HPV primary to co-testing. Outcomes included total and incremental differences in costs, invasive cervical cancer (ICC) cases, ICC deaths, number of colposcopies, and quality-adjusted life years for cost-effectiveness calculations.
KEY FINDINGS
-
The model predicted that screening with HPV primary testing instead of co-testing could lead to as many as 2,141 more ICC cases and 2,041 more ICC deaths.
-
Co-testing demonstrated a greater number of lifetime quality-adjusted life years (22,334) and yielded $39.0 million in savings compared with HPV primary, thereby conferring greater effectiveness at lower cost.
-
Model results demonstrate that co-testing has the potential to provide improved clinical and economic outcomes when compared with HPV primary.
-
DOWNLOAD THE ARTICLE HERE.
Additional Resources
The information in the Payer Tool is intended for payors, insurers or similar entities and should not be disseminated to health care providers making individual patient prescribing decisions.
